Well, I don't have a crystal ball. Not really. I think we are going sideways for a year or two.
The sad thing is that a pill will always trump injections. So PI-88, even if it meets the Phase III endpoints (results around 2011?), will never get the market penetration of Nexavar.
I think $1.00 could be the bottom. But don't be surprised if it goes lower.
